COVID-19. There’s a pill for that? Merck revs up production while waiting approval

RINewsToday

Photo: Merck A new drug, Molnupiravir, an investigational oral antiviral medicine, was shown to significantly reduce the risk of hospitalization or death for at risk, non-hospitalized adult patients with mild to moderate COVID-19. Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral…

Read More